What mechanisms cause lung cancer to lower cluster of differentiation 4 (CD4) counts, and what is the recommended workup and management?

Lung Cancer and Low CD4 Counts: Mechanisms, Workup, and Management

Lung cancer does not directly cause low CD4 counts through a specific pathophysiological mechanism—rather, low CD4 counts in lung cancer patients typically reflect concurrent HIV infection, immunosuppression from cancer treatment, or immune dysregulation within the tumor microenvironment.

Mechanisms of CD4 Alterations in Lung Cancer

Primary Considerations

The relationship between lung cancer and CD4 counts must be understood in context:

In HIV-positive patients with lung cancer, the low CD4 count is caused by HIV itself, not the lung cancer. Lung cancer is the most common non-AIDS-defining malignancy in people living with HIV (PLWH), accounting for approximately 11% of cancers in this population, with a 2-5 fold increased risk compared to HIV-negative individuals 1.

In the tumor microenvironment, CD4+ T cells undergo functional alterations rather than systemic depletion. Recent research demonstrates that specific CD4+ T-cell clusters, particularly CCR4-CCR6+ Th7R cells (a Th1-like subset), are actually enriched in tumor-draining lymph nodes and tumor microenvironments, with higher peripheral blood levels predicting favorable disease-free survival 2. This represents immune activation, not depletion.

Immune Microenvironment Changes

Within lung tumors, CD4+ T cells experience:

• Metabolic reprogramming: Nutrient competition with tumor cells, lactate accumulation, and altered glucose/amino acid availability impair CD4+ T-cell function 3
• Functional exhaustion: Upregulation of inhibitory receptors (PD-1, CTLA-4) on effector T cells
• Regulatory T-cell expansion: Increased Tregs suppress antitumor CD4+ responses
• Altered CD4:CD8 ratios: The CD4+/CD8+ ratio in bronchoalveolar lavage fluid is significantly lower in lung cancer patients compared to those with pulmonary infections, with diagnostic utility (AUC 0.712) 4

Workup for Lung Cancer

Initial Diagnostic Evaluation

All patients with suspected NSCLC should undergo 5, 6:

1. Thoracic CT scan with contrast (standard)

   • Include adrenal glands in imaging field
   • Use contiguous 5-8mm sections in hilar region

2. Tissue diagnosis

   • Bronchoscopy with deep samples
   • Transbronchial or transoesophageal needle biopsy with ultrasound guidance for mediastinal staging
   • Culture specimens for bacteria, fungi, and acid-fast bacilli (critical in immunosuppressed patients)

3. Mediastinal lymph node staging

   • Nodes >10mm diameter are suspicious and require sampling if results would change management
   • Mediastinoscopy or EBUS-guided sampling when N2/N3 involvement would alter treatment plan

4. PET-CT scanning (when available)

   • Detects approximately 20% more distant or N2/N3 metastases than conventional staging
   • Critical caveat: Requires confirmation of suspicious findings to prevent erroneous upstaging and denial of curative resection 5

Extrathoracic Staging (Symptom-Directed) 6

Standard workup includes:

• Liver ultrasound
• Brain CT with contrast (brain MRI preferred if available)
• Bone imaging only if painful symptoms present:
  • MRI for axial skeleton pain
  • Standard radiography with CT/MRI for other bone pain
  • Serum calcium and alkaline phosphatase

Serum tumor markers have no role in NSCLC workup 6.

Special Considerations for HIV-Positive Patients 1

All NSCLC patients should be tested for HIV if status unknown.

When lung cancer is diagnosed in PLWH:

1. Refer to HIV specialist if not already in care
2. Perform infectious disease workup for lung lesions before biopsy
   • Consider tuberculosis, fungal infections, infectious granulomas
   • Pulmonary Kaposi sarcoma (if suspected, biopsy with bleeding precautions)
3. Evaluate lymphadenopathy for nonmalignant causes
   • Mycobacterial infections
   • Non-Hodgkin lymphoma
4. Brain lesion workup in advanced immunosuppression
   • Rule out toxoplasmosis
   • Consider NHL
   • Consider empiric treatment before biopsy

Molecular and Immunohistochemical Testing 7

For adenocarcinoma histology:

• EGFR mutation testing (25% of tumors)
• ALK rearrangement testing
• Additional driver mutations: ROS1, RET, MET, KRAS
• PD-L1 expression (for immunotherapy eligibility)

For squamous cell carcinoma:

• PD-L1 expression
• Consider DDR2, FGFR testing in clinical trial settings

Management Approach

Stage-Specific Treatment

Early-stage (I-II): Surgical resection is standard 8

Locally advanced (III): Concurrent chemoradiotherapy for unresectable disease 8

Metastatic (IV) 8, 9:

• With EGFR mutations: First-line osimertinib (third-generation TKI)
  • For T790M resistance after first/second-generation TKIs: osimertinib
  • For progression on osimertinib: amivantamab + carboplatin/pemetrexed
• Without driver alterations: Platinum-based doublet chemotherapy (4-6 cycles maximum in responders)
• Second-line: Docetaxel, pemetrexed, or erlotinib

Immunotherapy Considerations 7

PD-L1 inhibitors require:

• Accurate histologic subclassification
• PD-L1 expression testing (specific assays for specific agents)
  • Pembrolizumab: 22C3 assay (scoring: <1%, 1-49%, ≥50%)
  • Atezolizumab: 28-8 assay (scoring: 1%, 5%, 10%)

Management in HIV-Positive Patients 1

Key principles:

1. Continue antiretroviral therapy (ART) throughout cancer treatment
2. Outcomes are similar to HIV-negative patients when appropriately treated
3. Opportunistic infection prophylaxis is critical during chemotherapy
4. Minimize steroid use (brief use acceptable for chemotherapy-induced nausea)
5. Increased infection risk requires vigilant monitoring

Common Pitfalls to Avoid

1. Do not assume low CD4 counts are caused by lung cancer alone—investigate for HIV, immunosuppressive medications, or other causes
2. Do not proceed with thoracotomy based on PET findings alone—confirm suspicious N2/N3 or M1 disease histologically to avoid denying curative surgery 5
3. Do not perform bone scans or brain imaging in asymptomatic early-stage patients—low yield and potential for false positives 6
4. Do not use serum tumor markers for diagnosis or staging 6
5. In PLWH, do not biopsy lung lesions without infectious disease workup—treat potential infections first 1